Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.

Cancer research - 1 Sept 2012

Floc'h Nicolas, Kinkade Carolyn Waugh, Kobayashi Takashi, Aytes Alvaro, Lefebvre Celine, Mitrofanova Antonina, Cardiff Robert D, Califano Andrea, Shen Michael M, Abate-Shen Cory

Abstract excerpt

Although the prognosis for clinically localized prostate cancer is now favorable, there are still no curative treatments for castration-resistant prostate cancer (CRPC) and, therefore, it remains fatal. In this study, we investigate a new therapeutic approach for treatment of CRPC, which involves dual targeting of a major signaling pathway that is frequently deregulated in the disease. We found that dual...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Heterocyclic Compounds, 3-Ring
Share to Orchiectomy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins c-akt

Share to Retinoblastoma Protein

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 22815528
DOI: 10.1158/0008-5472.CAN-12-0283
PMCID: PMC3432676

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.PMID 22815528Read ↗

Modeling prostate cancer in mice: limitations and opportunities.Semantic proximity Read ↗

Differential impact of PI3K/AKT/mTOR signaling on tumor initiation and progression in animal models of prostate cancer.Semantic proximity Read ↗

Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer.Semantic proximity Read ↗

PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer.Semantic proximity Read ↗

PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancerSemantic proximity Read ↗

PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.Semantic proximity Read ↗

PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathwaysSemantic proximity Read ↗

The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistanceSemantic proximity Read ↗

CUDC‐907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of actionSemantic proximity Read ↗

Involvement of PI3K/Akt pathway in prostate cancer--potential strategies for developing targeted therapies.Semantic proximity Read ↗

Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth.Semantic proximity Read ↗

Prostate Power Play: Does Pik3ca Accelerate Pten -Deficient Cancer Progression?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.